Acrivon Therapeutics names Michaela Levin chief business officer

PUBT · 3d ago
Acrivon Therapeutics names Michaela Levin chief business officer
  • Acrivon Therapeutics appointed Michaela Levin as chief business officer, effective Aug. 31, 2026.
  • Levin most recently served as vice president of business development at Recursion, formerly Exscientia, an AI platform company.
  • She previously held business development roles at Editas Medicine, Ovid Therapeutics, Constellation Pharmaceuticals, Harvard University, Mass General Brigham.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Acrivon Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202608310830PRIMZONEFULLFEED9817954) on August 31, 2026, and is solely responsible for the information contained therein.